OptimizeRx Corporation announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy.
The changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with long-term strategic objectives.
Key advancements include appointments in financial, commercial, legal, product & technology, operating, and business roles.
Ed Stelmakh Appointed CFSO
Ed Stelmakh has been appointed Chief Financial & Strategic Officer to encompass broader strategy alongside financial leadership, focusing on achieving Rule of 40 in 2-3 years.
Theresa Greco Continues as CCO
Theresa Greco, Chief Commercial Officer, will focus on transitioning to a recurring revenue model to drive sustainable revenue growth.
Marion Odence-Ford Named CLAO
Marion Odence-Ford has an expanded role as Chief Legal & Administrative Officer, overseeing key administrative functions and legal matters.
Doug Besch Leads Product & Technology
Doug Besch, Chief Product & Technology Officer, will drive product enhancements, platform optimization, data, and partnership efforts.
Brendan Merrell Promoted to COO
Brendan Merrell, Chief Operating Officer, will focus on operational excellence and driving operating leverage across the Company.
- The leadership advancements aim to align talent with the Company's strategic objectives for sustained growth and increased profitability.
- The focus on key areas like financial strategy, commercial growth, legal governance, product development, operational excellence, and strategic planning is crucial for OptimizeRx's future success.
The announced leadership advancements at OptimizeRx Corporation demonstrate a clear commitment to driving profitable growth and aligning talent with long-term strategies. These strategic moves are expected to position the Company for continued success in the healthcare technology sector.